electroCore announced an agreement with Byond Healthcare Pty to serve as the exclusive distributor of gammaCore Sapphire, non-invasive vagus nerve stimulator, nVNS, in South Africa and Namibia. "Access to exceptional medical technologies is key to improving healthcare outcomes," said David Loubser, Managing Director of Byond Healthcare. "It is a privilege for Byond to provide clinicians in South Africa and Namibia with a cutting-edge, clinically proven tool that we believe can help combat the opioid crisis by treating a variety of pain conditions with a non-pharmaceutical therapeutic option. Cleared by reputable authorities such as the U.S. FDA, TGA, Health Canada, and EU, gammaCore is a practical solution that aligns with Byond’s focus on making innovative pain management technologies accessible to both patients and healthcare providers. As a first-line treatment option for primary headache-related pain, gammaCore is a perfect fit for Byond’s mission." The initial term of the agreement is three years and contains customary terms and conditions, and regulatory clearances are required before sales and revenue can occur.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ECOR:
